Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest…

Since becoming only the second Alzheimer’s-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024. In its Phase 3 clinical trial, lecanemab slowed cognitive decline by 27 per cent overall, yet one subset of data suggested little to no benefit in females, though the cause of the difference was not clear. An FDA committee voted unanimously that the…

Previous exposures to older flu strains prime the immune system to produce antibodies against H5N1, and children would likely benefit the most from H5N1 vaccinations Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian influenza virus, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Older adults who were exposed to seasonal flu viruses that circulated prior to 1968 were found to be more likely to have…

New study tested tiny fragments of future drugs and may lead to new therapies to treat this deadly disease The immune system typically can ramp up the body’s defenses to clear out an invading threat without issue. Glitches can happen, however, with sepsis occurring when the mustered army of cells also attacks the body’s own tissues and organs as if they were enemy combatants. Sepsis is dangerous, particularly when it isn’t treated early, and it can lead to the even…